Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study
暂无分享,去创建一个
E. Iannitto | M. Federico | C. Tripodo | C. Haioun | R. Gressin | M. Merli | E. Zucca | S. Zupo | F. Re | A. Ferreri | L. Marcheselli | L. Baseggio | C. Thieblemont | A. Liberati | A. Perrot | F. Palombi | C. Stelitano | C. Patti | S. Mancuso | B. Castagnari | K. Bouabdallah | A. Gulino | M. Bellei | G. Gini | M. Cabras | S. Amorim | B. Tessoulin | A. Traverse-Glehen | I. Álvarez | M. Cesaretti | J. Dupuis
[1] P. Korkolopoulou,et al. Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance. , 2018, Blood.
[2] L. Bergamaschini,et al. First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas , 2018, Medical Oncology.
[3] Juan F. García,et al. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. , 2017, Blood.
[4] M. Angelopoulou,et al. Treatment of splenic marginal zone lymphoma. , 2017, Best practice & research. Clinical haematology.
[5] M. Piris,et al. Splenic marginal zone lymphoma. , 2017, Best practice & research. Clinical haematology.
[6] R. Foà,et al. Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era. , 2016, Leukemia research.
[7] J. Pérez-Simón,et al. Role of 18F‐FDG‐PET/CT in the management of marginal zone B cell lymphoma , 2015, Hematological oncology.
[8] R. Foà,et al. Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. , 2015, Leukemia research.
[9] R. Gascoyne,et al. Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia , 2015, British journal of haematology.
[10] E. Iannitto,et al. Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study , 2015, Leukemia & lymphoma.
[11] J. Burke,et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. , 2014, Blood.
[12] G. Salles,et al. Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment , 2014, Leukemia & lymphoma.
[13] A. Olszewski,et al. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma , 2014, Annals of Hematology.
[14] S. Galimberti,et al. Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] M. Stauch,et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial , 2013, The Lancet.
[16] N. Schmitz,et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] P. Korkolopoulou,et al. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy. , 2013, The oncologist.
[18] D. Catovsky,et al. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma , 2012, British journal of haematology.
[19] A. Salar,et al. Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases , 2012, British journal of haematology.
[20] N. Kearney,et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. , 2011, European journal of cancer.
[21] E. Orciuolo,et al. 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. , 2010, Leukemia research.
[22] A. Salar,et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria , 2008, Leukemia.
[23] J. Leonard,et al. FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma , 2008, Leukemia & lymphoma.
[24] L. Fleisher,et al. Risk stratification. , 2008, Best practice & research. Clinical anaesthesiology.
[25] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] K. Do,et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone , 2006, Cancer.
[27] E. Iannitto,et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. , 2006, Blood.
[28] E. Iannitto,et al. Splenic marginal zone lymphoma with or without villous lymphocytes , 2004, Cancer.
[29] M Schemper,et al. A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.